LivaNova PLC
LIVN
Pozycja w akcjach
#3786
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Cena akcji
$80.35
Ostatnia synchronizacja: 2026-10-20
Kapitalizacja rynkowa
$4.41B
Zmiana (1 dzień)
2.83%
Zmiana (1 rok)
46.87%
Kraj
GB
Handel LivaNova PLC (LIVN)
Kategoria
Healthcare
Zyski dla LivaNova PLC (LIVN)
Zyski w Jun 2026 TTM: $106.69M
Według najnowszych raportów finansowych LivaNova PLC, obecny zysk firmy wynosi $106.69M. W roku 2023 firma osiągnęła zysk w wysokości $-81.33M, spadek w porównaniu do zysku z roku 2022, który wynosił $-75.20M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy LivaNova PLC od 2000 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $106.69M | 20.81% |
| 2024 | $88.31M | -208.58% |
| 2023 | $-81.33M | 8.16% |
| 2022 | $-75.20M | -39.66% |
| 2021 | $-124.62M | -64.22% |
| 2020 | $-348.29M | 172.89% |
| 2019 | $-127.63M | -48.41% |
| 2018 | $-247.40M | -304.29% |
| 2017 | $121.10M | -466.97% |
| 2016 | $-33.00M | -136.96% |
| 2015 | $89.29M | 11.79% |
| 2014 | $79.88M | 6.12% |
| 2013 | $75.27M | 24.58% |
| 2012 | $60.42M | 24.16% |
| 2011 | $48.66M | 26.44% |
| 2010 | $38.49M | 40.21% |
| 2009 | $27.45M | -358.97% |
| 2008 | $-10.60M | -79.26% |
| 2007 | $-51.10M | -13.34% |
| 2006 | $-58.97M | 383.67% |
| 2005 | $-12.19M | -274.42% |
| 2004 | $6.99M | 31.53% |
| 2003 | $5.31M | -119.60% |
| 2002 | $-27.12M | 412.06% |
| 2000 | $-5.30M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $7.51B | 6,940.15% |
US
|
|
| $5.56B | 5,114.27% |
IE
|
|
| $5.15B | 4,725.28% |
US
|
|
| $3.86B | 3,518.96% |
US
|
|
| - | - |
DE
|
